Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.58 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.52 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 3/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11683055 | 0.88 | PLA2G4B (0.61) | PLA2G4BTBXAS1LTB4RLTB4R2ALOX15 | |
| SCHEMBL11684213 | 0.86 | PLA2G4B (0.69) | PLA2G4BTBXAS1LTB4RLTB4R2ALOX15 | |
| SCHEMBL19679582 | 0.86 | SRD5A2 (0.54) | LTA4HPLA2G4BTBXAS1PLA2G2ALTB4R | |
| SCHEMBL2628195 | 0.85 | PLA2G4B (0.55) | PLA2G4BTBXAS1LTB4RLTB4R2ALOX15 | |
| SCHEMBL8475224 | 0.85 | TBXAS1 (0.55) | LTA4HTBXAS1LMNACA2 | |
| SCHEMBL2628191 | 0.85 | PLA2G4B (0.55) | PLA2G4BTBXAS1LTB4RLTB4R2ALOX15 | |
| SCHEMBL11351141 | 0.85 | CA2 (0.52) | PLA2G4BTBXAS1LMNACA2CAMK2A | |
| SCHEMBL11354239 | 0.84 | LTA4H (0.51) | LTA4HTAAR1PLA2G2AITGB3ITGA2B | |
| SCHEMBL10897821 | 0.84 | POLB (0.54) | LTA4HTAAR1PLA2G2AITGB3ITGA2B | |
| Hydrochloric Acid SCHEMBL8938138 | 0.84 | TBXAS1 (0.54) | LTA4HTBXAS1LMNACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
| US-6657063-B1 | (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino) ethoxy)phenyl)acetic acid derivatives; dietetics; hypotensive agents; non-insulin dependent diabetes treatment | PFIZER INC. | 2003-12-02 | — | — | US | disclosed |
| EP-1060178-B1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6610707-B1 | Moderate neuronal regeneration and outgrowth and can be used for treating neurological disorders arising from neurodegenerative diseases and nerve damage. | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| EP-1060178-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 2000-12-20 | — | — | EP | disclosed |
| WO-1999045006-A1 | HETEROCYCLIC COMPOUNDS AS INHIBITORS OF ROTAMASE ENZYMES | PFIZER INC. (US) | 1999-09-10 | — | — | WO | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | LTA4H 1175/4885PLA2G4B 3016/4885TAAR1 742/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | LTA4H 1742/4885PLA2G4B 2191/4885TAAR1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.